On June 24, RemeGen (09995.HK) rose 5.31% in regular trading, trading at HKD 70.05/share, with turnover of HKD 131 million.

On the news front, the HK biotech sector rallied for a second consecutive session, with AKESO up 4.33%, INNOVENT BIO up 3.92%, 3SBIO up 4.99%, BEIGENE up 3.6%, and SKB BIO up 7.44%, reflecting continued recovery in sector sentiment following the prior week's sell-off.

Additionally, the company previously announced that 193 million restricted shares from its IPO will become eligible for trading on July 1, representing 34.16% of total share capital. However, because the company has not met cash dividend distribution requirements under Shanghai Stock Exchange regulations, the unlocking shareholders are prohibited from reducing holdings through centralized bidding or block trading on A-shares. This regulatory restriction has substantially reduced actual selling pressure expectations, further alleviating market concerns over the potential overhang impact from the lock-up expiration.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)